Reneo Pharmaceuticals completed the merger with OnKure.

Reneo Pharmaceuticals, a pharmaceutical company, completed the merger with OnKure, a privately-held, clinical-stage biopharmaceutical company. Financial terms were not disclosed. “We are ecstatic to finalize this merger, and move to accelerate the development of our mutant-specific PI3Kα inhibitor portfolio. Combined with our unique expertise in PI3K-mutated cancers, we aim to fully target and exploit the vulnerabilities of this oncogenic menace for the benefit of patients suffering needlessly. Our lead program OKI-219, a highly selective inhibitor of PI3KαH1047R, has the potential to provide benefit to breast cancer patients,” Nicholas Saccomano, OnKure President and CEO.